<DOC>
	<DOCNO>NCT01663727</DOCNO>
	<brief_summary>This Phase III , randomize , double-blind , placebo-controlled multicenter study evaluate efficacy safety bevacizumab administer combination paclitaxel patient previously untreated , locally recurrent , metastatic HER2-negative breast cancer . Patients randomize one two treatment arm : bevacizumab placebo . All patient give intravenous ( IV ) infusion paclitaxel ( 90 mg/m2 ) 3 week 28-day cycle . bevacizumab placebo ( 10 mg/kg ) administer IV infusion Days 1 15 28-day cycle . Patients treat disease progression , unacceptable toxicity death cause occur .</brief_summary>
	<brief_title>Study To Evaluate Efficacy Safety Of Bevacizumab , Associated Biomarkers , In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically cytologically confirm , HER2negative adenocarcinoma breast , measurable nonmeasurable locally recurrent metastatic disease . Locally recurrent disease must amenable resection curative intent . ECOG performance status 0 1 For woman childbearing potential , use acceptable effective method nonhormonal contraception For patient receive recent radiotherapy , recovery prior randomization significant acute toxicity , radiation treatment complete 3 week randomization DiseaseSpecific Exclusions : HER2positive status Prior chemotherapy locally recurrent metastatic disease Prior hormonal therapy &lt; 2 week prior randomization Prior adjuvant neoadjuvant chemotherapy allow , provide conclusion least 12 month prior randomization Investigational therapy within 28 day randomization General Medical Exclusions : Life expectancy &lt; 12 week Inadequate organ function Uncontrolled serious medical psychiatric illness Active infection require intravenous ( IV ) antibiotic screen Pregnancy lactation History malignancy within 5 year prior screen , except tumor negligible risk metastasis death</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>